Sympathomimetics history

Advanced arteriosclerosis symptomatic cardiovascular disease moderate to severe hypertension hyperthyroidism hypersensitivity or idiosyncrasy to the sympathomimetic amines glaucoma agitated states history of drug abuse during or within 14 days following administration of monoamine oxidase (MAO) inhibitors (hypertensive crises may result). 

I Contraindications Advanced arteriosclerosis, agitated states, glaucoma, history of drug abuse, history of hypersensitivity to sympathomimetic amines, hyperthyroidism, moderate to severe hypertension, symptomatic cardiovascular disease, within 14 days following discontinuation of an MAOI... 

Contraindications Agitated states, use of MAOIs within 14 days, glaucoma, history of drug abuse, hyperthyroidism, advanced arteriosclerosis or severe cardiovascular disease, severe hypertension, and hypersensitivity to sympathomimetic amines... 

Sympathomimetics can be physically addictive and should not be prescribed to people with a history of drug abuse. A person may develop a tolerance to the drug and attempt to increase the dosage. The person may develop intoxication symptoms such as insomnia and severe skin diseases. 

Tachycardia, dysrhythmias, and a rise in blood pressure have been described after the administration of centrally acting sympathomimetic amines. Amfetamine acutely administered to men with a history of amfetamine abuse enhanced the pressor effects of tyramine and noradrenaline, while continuous amfetamine led to tolerance of the pressor response to tyramine. As with intravenous amphetamines, cardiomyopathy, cardiomegaly, and pulmonary edema have been reported with smoking of crystal metamfetamine (15-17). 

ADVERSE EFFECTS Dronabinol has complex effects on the CNS, including a prominent central sympathomimetic activity that can lead to palpitations, tachycardia, vasodilation, hypotension, and conjunctival injection (bloodshot eyes). Patient supervision is necessary because marijuana-hke highs e.g., euphoria, somnolence, detachment, dizziness, anxiety, nervousness, panic, etc.) can occur, as can more disturbing effects such as paranoid reactions and thinking abnormalities. After abrupt withdrawal of dronabinol, an abstinence syndrome manifest by irritability, insomnia, and restlessness can occur. Because of its high affinity for plasma proteins, dronabinol can displace other plasma protein-bound drugs, whose doses may have to be adjusted as a consequence. Dronabinol should be prescribed with great caution to persons with a history of substance abuse because it also may be abused by these patients. 

IV. Diagnosis is usually based on a history of amphetamine use and clinical features of sympathomimetic drug intoxication. 

IV. Diagnosis is based on clinical features of sympathomimetic drug intoxication with a history of MAO inhibitor use, particularly with use of drugs or foods known to interact. Serotonin syndrome (see p 22) is suspected when the patient has myoclonic jerking, hyperreflexia, diaphoresis, and hyperthermia. 

Serious adverse events are uncommon with the cannabinoid agonists. Their interactions with the central nervous system are complex and not well understood, but include sympathomimetic effects that can lead to tachycardia and, occasionally, postural hypotension, which may lead to cardiac events in susceptible patients. Psychotic reactions and seizures can he precipitated in some patients with a history or genetic predisposition to these disorders. 

---